Role of resveratrol in the management of insulin resistance and related conditions: Mechanism of action

References

• Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32(9):1431–1437.
   PubMed Web of Science ®Google Scholar
• Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21(12):1443–1455.
   PubMed Web of Science ®Google Scholar
• Guariguata L, Whiting D, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149.
   PubMed Web of Science ®Google Scholar
• Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89(6):2601–2607.
   PubMed Web of Science ®Google Scholar
• Marsh JB. Lipoprotein metabolism in obesity and diabetes: insights from stable isotope kinetic studies in humans. Nutr Rev. 2003;61(11):363–375.
   PubMed Web of Science ®Google Scholar
• Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23(2):201–229.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014; 383(9922):1068–1083.
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Insulin resistance is central to the burden of diabetes. Diabetes Metab Rev. 1997;13(2):81–86.
   PubMed Web of Science ®Google Scholar
• Kuhnle G, Spencer JP, Chowrimootoo G, et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun. 2000;272(1):212–217.
   PubMed Web of Science ®Google Scholar
• Szkudelski T, Szkudelska K. Anti‐diabetic effects of resveratrol. Ann NY Acad Sci. 2011;1215:34–39.
   PubMed Web of Science ®Google Scholar
• Timmers S, Hesselink MK, Schrauwen P. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann NY Acad Sci. 2013;1290(1):83–89.
   PubMed Web of Science ®Google Scholar
• de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: can resveratrol relieve metabolic disturbances? Biochim Biophys Acta. 2015;1852(6):1137–1144.
   PubMed Web of Science ®Google Scholar
• Aguirre L, Fernández-Quintela A, Arias N, et al. Resveratrol: anti-obesity mechanisms of action. Molecules. 2014;19:18632–18655.
   PubMed Web of Science ®Google Scholar
• Lopez-Velez M, Martinez-Martinez F, Valle-Ribes CD. The study of phenolic compounds as natural antioxidants in wine. Crit Rev Food Sci Nutr. 2003;43:233–244.
   PubMed Web of Science ®Google Scholar
• Zhirongwang Yh, Jiangangzou K, Yinan X, et al. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med. 2002;9:77–79.
   PubMed Web of Science ®Google Scholar
• Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2(5):270–278.
   PubMed Web of Science ®Google Scholar
• Sies H. Polyphenols and health: update and perspectives. Arch Biochem Biophys. 2010;501(1):2–5.
   PubMed Web of Science ®Google Scholar
• Pangeni R, Sahni JK, Ali J, et al. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv. 2014;11(8):1285–1298.
   PubMed Web of Science ®Google Scholar
• Kuršvietienė L, Stanevičienė I, Mongirdienė A, Bernatonienė J. Multiplicity of effects and health benefits of resveratrol. Medicina. 2016;52(3):148–155.
   PubMed Web of Science ®Google Scholar
• Fornara V, Onelli E, Sparvoli F, et al. Localization of stilbene synthase in Vitis vinifera L. during berry development. Protoplasma. 2008;233(1–2):83–93.
   PubMed Web of Science ®Google Scholar
• Ho RC, Davy K, Davy B, et al. Whole-body insulin sensitivity, low-density lipoprotein (LDL) particle size, and oxidized LDL in overweight, nondiabetic men. Metabolism. 2002;51(11):1478–1483.
   PubMed Web of Science ®Google Scholar
• Yu CK, Springob K, Schmidt J, et al. A stilbene synthase gene (SbSTS1) is involved in host and nonhost defense responses in sorghum. Plant Physiol. 2005;138(1):393–401.
   PubMed Web of Science ®Google Scholar
• Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem. 1997;30(2):91–113.
   PubMed Web of Science ®Google Scholar
• Curtin A, Deegan P, Owens D, et al. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol. 1996;33(3):205–210.
   PubMed Web of Science ®Google Scholar
• Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab. 2006;290(6):E1339–E1346.
   PubMed Web of Science ®Google Scholar
• Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–342.
   PubMed Web of Science ®Google Scholar
• Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem. 2005;16(8):449–466.
   PubMed Web of Science ®Google Scholar
• Weiskirchen S, Weiskirchen R. Resveratrol: How much wine do you have to drink to stay healthy? Adv Nutr. 2016;7(4):706–718.
   PubMed Web of Science ®Google Scholar
• Planas JM, Alfaras I, Colom H, et al. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys. 2012;527(2):67–73.
   PubMed Web of Science ®Google Scholar
• Walle T, Walle UK, Sedmera D, et al. Benzo[A]pyrene-induced oral carcinogenesis and chemoprevention: studies in bioengineered human tissue. Drug Metab Dispos. 2006;34(3):346–350.
   PubMed Web of Science ®Google Scholar
• Smoliga JM, Blanchard O. Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules. 2014;19(11):17154–17172.
   PubMed Web of Science ®Google Scholar
• Walle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377–1382.
   PubMed Web of Science ®Google Scholar
• Tomé-Carneiro J, Larrosa M, González-Sarrías A, et al. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013;19(34):6064–6093.
   PubMed Web of Science ®Google Scholar
• Vaz-da-Silva M, Loureiro AI, Falcao A, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther. 2008;46(11):564–570.
   PubMed Web of Science ®Google Scholar
• la Porte C, Voduc N, Zhang G, et al. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010;49(7):449–454.
   PubMed Web of Science ®Google Scholar
• Yu KC, Mamo JC. Chylomicron-remnant-induced foam cell formation and cytotoxicity: a possible mechanism of cell death in atherosclerosis. Clin Sci. 2000;98(2):183–192.
   PubMed Web of Science ®Google Scholar
• Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1246–1252.
   PubMed Web of Science ®Google Scholar
• Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(Suppl1):S7–S15.
   Web of Science ®Google Scholar
• Ortuno J, Kontaxakis G, Rubio J, et al. Efficient methodologies for system matrix modelling in iterative image reconstruction for rotating high-resolution PET. Phys Med Biol. 2010;55(7):1833.
   PubMed Web of Science ®Google Scholar
• Gambini J, Inglés M, Olaso G, et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev. 2015;2015:837042.
   PubMed Web of Science ®Google Scholar
• Marier JF, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharm Exp Ther. 2002;302(1):369–373.
   PubMed Web of Science ®Google Scholar
• Jannin B, Menzel M, Berlot JP, et al. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol. 2004;68(6):1113–1118.
   PubMed Web of Science ®Google Scholar
• Vitrac X, Desmouliere A, Brouillaud B, et al. Distribution of [14 C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003;72(20):2219–2233.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang Y-J, Qian H-Y, et al. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev. 2012;17(3):437–448.
   PubMed Web of Science ®Google Scholar
• Das S, Falchi M, Bertelli A, et al. Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung. 2006;56(10):700–706.
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.
   PubMed Web of Science ®Google Scholar
• Frémont L, Belguendouz L, Delpal S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci. 1999;64(26):2511–2521.
   PubMed Web of Science ®Google Scholar
• Bhat KP, Pezzuto JM. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 2001;61(16):6137–6144.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Dudley JI, Das DK. Dose-dependency of resveratrol in providing health benefits. Dose Response. 2010;8(4):478–500.
   PubMed Web of Science ®Google Scholar
• Penumathsa SV, Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. This article is one of a selection of papers from the NATO Advanced Research Workshop on Translational Knowledge for Heart Health. Can J Physiol Pharmacol. 2009;87(4):275–286.
   PubMed Web of Science ®Google Scholar
• Meydani M, Hasan ST. Dietary polyphenols and obesity. Nutrients. 2010;2(7):737–751.
   PubMed Web of Science ®Google Scholar
• Hebbar V, Shen G, Hu R, et al. Toxicogenomics of resveratrol in rat liver. Life Sci. 2005;76(20):2299–2314.
   PubMed Web of Science ®Google Scholar
• Crowell JA, Korytko PJ, Morrissey RL, et al. Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82(2):614–619.
   PubMed Web of Science ®Google Scholar
• Williams LD, Burdock GA, Edwards JA, et al. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 2009;47(9):2170–2182.
   PubMed Web of Science ®Google Scholar
• Vang O. What is new for resveratrol? Is a new set of recommendations necessary? Ann NY Acad Sci. 2013;1290(1):1–11.
   PubMed Web of Science ®Google Scholar
• Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003–9011.
   PubMed Web of Science ®Google Scholar
• Zamora-Ros R, Urpí-Sardà M, Lamuela-Raventos RM, et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem. 2006;52(7):1373–1380.
   PubMed Web of Science ®Google Scholar
• Chow HS, Garland LL, Hsu CH, et al. Resveratrol modulates drug-and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res. 2010;3(9):1168–1175.
   PubMed Web of Science ®Google Scholar
• Movahed A1, Nabipour I, Lieben Louis X, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267.
   PubMed Web of Science ®Google Scholar
• Szkudelski T, Szkudelska K. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 2015;1852(6):1145–1154.
   PubMed Web of Science ®Google Scholar
• Dash S, Xiao C, Morgantini C, et al. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler Thromb Vasc Biol. 2013;33(12):2895–2901.
   PubMed Web of Science ®Google Scholar
• Sanchez-Fidalgo S, Cardeno A, Villegas I, et al. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol. 2010;633(1–3):78–84.
   PubMed Web of Science ®Google Scholar
• Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(03):383–389.
   PubMed Web of Science ®Google Scholar
• Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta. 1996;246(1–2):163–182.
   PubMed Web of Science ®Google Scholar
• Kennedy A, Overman A, LaPoint K, et al. Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol. J Lipid Res. 2009;50(2):225–232.
   PubMed Web of Science ®Google Scholar
• Kim S, Jin Y, Choi Y, et al. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011;81(11):1343–1351.
   PubMed Web of Science ®Google Scholar
• Minakawa M, Kawano A, Miura Y, et al. Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic β-cells. J Clin Biochem Nutr. 2011;48(3):237–244.
   PubMed Web of Science ®Google Scholar
• Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 2003;73(11):1393–1400.
   PubMed Web of Science ®Google Scholar
• Ahn J, Cho I, Kim S, et al. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol. 2008;49(6):1019–1028.
   PubMed Web of Science ®Google Scholar
• Turrens JF, Lariccia J, Nair MG. Resveratrol has no effect on lipoprotein profile and does not prevent peroxidation of serum lipids in normal rats. Free Radic Res. 1997;27(6):557–562.
   PubMed Web of Science ®Google Scholar
• Berrougui H, Grenier G, Loued S, et al. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009;207(2):420–427.
   PubMed Web of Science ®Google Scholar
• Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase–deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59(3):554–563.
   PubMed Web of Science ®Google Scholar
• Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health – a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011;55(8):1129–1141.
   PubMed Web of Science ®Google Scholar
• Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–1122.
   PubMed Web of Science ®Google Scholar
• Zang M, Xu S, Maitland-Toolan KA, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor–deficient mice. Diabetes. 2006;55(8):2180–2191.
   PubMed Web of Science ®Google Scholar
• Fischer-Posovszky P, Kukulus V, Tews D, et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010;92(1):5–15.
   PubMed Web of Science ®Google Scholar
• Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007;6(6):759–767.
   PubMed Web of Science ®Google Scholar
• Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur J Pharmacol. 2006;552(1):176–181.
   PubMed Web of Science ®Google Scholar
• Cottart CH, Nivet‐Antoine V, Laguillier‐Morizot C, et al. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 2010;54(1):7–16.
   PubMed Web of Science ®Google Scholar
• Park E-J, Pezzuto JM. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta. 2015;1852(6):1071–1113.
   PubMed Web of Science ®Google Scholar
• Baile CA, Yang JY, Rayalam S, et al. Effect of resveratrol on fat mobilization. Ann NY Acad Sci. 2011;1215(1):40–47.
   PubMed Web of Science ®Google Scholar
• Ramprasath V, Jones P. Anti-atherogenic effects of resveratrol. Eur E J Clin Nutr. 2010;64:660–668.
   PubMed Web of Science ®Google Scholar
• Faghihzadeh F HA, Adibi P. Resveratrol and liver: a systematic review. J Res Med Sci. 2015;20:797–810.
   PubMed Web of Science ®Google Scholar
• Su Q, Baker C, Christian P, et al. Hepatic mitochondrial and ER stress induced by defective PPARα signaling in the pathogenesis of hepatic steatosis. Am J Physiol Endocrinol Metab. 2014;306(11):E1264–E1273.
   PubMed Web of Science ®Google Scholar
• Hoehn KL, Salmon AB, Hohnen-Behrens C, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA. 2009;106(42):17787–17792.
   PubMed Web of Science ®Google Scholar
• Boden MJ, Brandon AE, Tid-Ang JD, et al. Overexpression of manganese superoxide dismutase ameliorates high-fat diet-induced insulin resistance in rat skeletal muscle. Am J Physiol Endocrinol Metab. 2012;303(6):E798–E805.
   PubMed Web of Science ®Google Scholar
• Ingram KH, Hill H, Moellering DR, et al. Skeletal muscle lipid peroxidation and insulin resistance in humans. J Clin Endocrinol Metab. 2012;97(7):E1182–E1186.
   PubMed Web of Science ®Google Scholar
• Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med. 2011;51(5):993–999.
   PubMed Web of Science ®Google Scholar
• Schrauwen P. Lipid-induced cell stress and insulin resistance. Food Nutr Sci. 2006;50:62–67.
   Google Scholar
• Ragheb R, Shanab GM, Medhat AM, et al. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun. 2009;389(2):211–216.
   PubMed Web of Science ®Google Scholar
• Tsai JW, Zhang R, Qiu W, et al. Inflammatory nuclear factor kappa B activation promotes hepatic apolipoprotein B100 secretion. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1287–G1298.
   PubMed Web of Science ®Google Scholar
• Slater SJ, Seiz JL, Cook AC, et al. Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta. 2003;1637(1):59–69.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Lee F, DePaoli-Roach A, et al. Phosphorylation of glycogen synthase by the Ca2+-and phospholipid-activated protein kinase (protein kinase C). J Biol l Chem. 1984;259(14):8743–8747.
   PubMed Web of Science ®Google Scholar
• Penumathsa SV, Thirunavukkarasu M, Zhan L, et al. Resveratrol enhances GLUT‐4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Mol Cell Med. 2008;12(6a):2350–2361.
   PubMed Web of Science ®Google Scholar
• Thirunavukkarasu M, Penumathsa SV, Koneru S, et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med. 2007;43(5):720–729.
   PubMed Web of Science ®Google Scholar
• Cao Z, Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol. 2004;489:39–48.
   PubMed Web of Science ®Google Scholar
• Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2):171–176.
   PubMed Web of Science ®Google Scholar
• Kawanaka K, Han D-H, Gao J, et al. Development of glucose-induced insulin resistance in muscle requires protein synthesis. J Biol Chem. 2001;276(23):20101–20107.
   PubMed Web of Science ®Google Scholar
• Marshall S, Bacote V, Traxinger R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266(8):4706–4712.
   PubMed Web of Science ®Google Scholar
• Sung MM, Kim TT, Denou E, et al. Improved glucose homeostasis in obese mice treated with resveratrol is associated with alterations in the gut microbiome. Diabetes. 2017;66(2):418–425.
   PubMed Web of Science ®Google Scholar
• Rivera L, Morón R, Zarzuelo A, et al. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053–1063.
   PubMed Web of Science ®Google Scholar
• Crandall JP, Oram V, Trandafirescu G, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 2012;67:1307–1312.
   PubMed Web of Science ®Google Scholar
• Chi TC, Chen WP, Chi TL, et al. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci. 2007;80(18):1713–1720.
   PubMed Web of Science ®Google Scholar
• Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metabol. 2012;15(5):675–690.
   PubMed Web of Science ®Google Scholar
• Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92(3):1479–1514.
   PubMed Web of Science ®Google Scholar
• Chen T, Li J, Liu J, et al. Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway. Am J Physiol Heart Circ Physiol. 2015;308(5):H424–H434.
   PubMed Web of Science ®Google Scholar
• Shi T, Wang F, Stieren E, et al. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005;280(14):13560–13567.
   PubMed Web of Science ®Google Scholar
• Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des. 2009;74(6):619–624.
   PubMed Web of Science ®Google Scholar
• Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007;6(4):307–319.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez Á, Gutierrez JAM, Sanz-González S, et al. Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes. 2010;59(3):588–599.
   PubMed Web of Science ®Google Scholar
• Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA. 2002;99(17):11357–11362.
   PubMed Web of Science ®Google Scholar
• Rodgers JT, Lerin C, Haas W, et al. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature. 2005;434(7029):113–118.
   PubMed Web of Science ®Google Scholar
• Vats V, Grover J, Rathi S. Evaluation of anti-hyperglycemic and hypoglycemic effect of Trigonella foenum-graecum Linn, Ocimum sanctum Linn and Pterocarpus marsupium Linn in normal and alloxanized diabetic rats. J Ethnopharmacol. 2002;79(1):95–100.
   PubMed Web of Science ®Google Scholar
• Gómez-Zorita S, Fernández-Quintela A, Lasa A, et al. Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats, Nutrition. 2013;29:1374–1380.
   PubMed Web of Science ®Google Scholar
• Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic β-cells against cytokine toxicity by suppressing the nuclear factor-κB signaling pathway. Diabetes. 2009;58(2):344–351.
   PubMed Web of Science ®Google Scholar
• Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice. Cell Metabo. 2005;2(2):105–117.
   PubMed Web of Science ®Google Scholar
• Kang W, Hong HJ, Guan J, et al. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism. 2012;61(3):424–433.
   PubMed Web of Science ®Google Scholar
• Hong HJ, Kang W, Kim DG, et al. Effects of resveratrol on the insulin signaling pathway of obese mice. J Vet Sci. 2014;15(2):179–185.
   PubMed Web of Science ®Google Scholar
• Saha AK, Xu XJ, Balon TW, et al. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? Cell Cycle. 2011;10(20):3447–3451.
   PubMed Web of Science ®Google Scholar
• Sidiropoulos KG, Meshkani R, Avramoglu-Kohen R, et al. Insulin inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site (IRES) initiation. Arch Biochem Biophys. 2007;465(2):380–388.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhou R, Wang B, et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2014;99(6):1510–1519.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care. 2006;29(1):S43–S48.
   PubMedGoogle Scholar
• Donath MY, Ehses JA, Maedler K, et al. Mechanisms of β-cell death in type 2 diabetes. Diabetes. 2005;54:S108–S113.
   PubMed Web of Science ®Google Scholar
• Hansen JB, Arkhammar G, Per O, et al. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem. 2004;11(12):1595–1615.
   PubMed Web of Science ®Google Scholar
• Pinent M, Castell A, Baiges I, et al. Bioactivity of flavonoids on insulin‐secreting cells. Compr Rev Food Sci Food Saf. 2008;7(4):299–308.
   PubMed Web of Science ®Google Scholar
• Palsamy P, Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic β‐cell dysfunction in streptozotocin‐nicotinamide‐induced diabetic rats. J Cell Physiol. 2010;224(2):423–432.
   PubMed Web of Science ®Google Scholar
• Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119:S10–S16.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Goldstein BJ. Effect of tumor necrosis factor‐α on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein‐tyrosine phosphatases. J Cell Biochem. 1997;64(1):117–127.
   PubMed Web of Science ®Google Scholar
• Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745–E751.
   PubMed Web of Science ®Google Scholar
• Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51(12):3391–3399.
   PubMed Web of Science ®Google Scholar
• Szkudelski T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. Am J Physiol Endocrinol Metab. 2007;293(4):E901–E907.
   PubMed Web of Science ®Google Scholar
• Szkudelski T. The insulin-suppressive effect of resveratrol—an in vitro and in vivo phenomenon. Life Sci. 2008;82(7):430–435.
   PubMed Web of Science ®Google Scholar
• Zhang C, Luo J, Yu B, Chen J, et al. Effects of resveratrol on lipid metabolism in muscle and adipose tissues: a reevaluation in a pig model. J Funct Foods. 2015;14:590–595.
   Web of Science ®Google Scholar
• Pithadia A, Brender JR, Fierke CA, et al. Inhibition of IAPP aggregation and toxicity by natural products and derivatives. J Diabetes Res. 2016;2016:2046327.
   PubMed Web of Science ®Google Scholar
• Stefani M, Rigacci S. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Med Sci. 2013;14(6):12411–12457.
   Web of Science ®Google Scholar
• Tu LH, Young LM, Wong AG, et al. Mutational analysis of the ability of resveratrol to inhibit amyloid formation by islet amyloid polypeptide: critical evaluation of the importance of aromatic–inhibitor and histidine–inhibitor interactions. Biochemistry. 2015;54(3):666–676.
   PubMed Web of Science ®Google Scholar
• Jiang P, Li W, Shea JE, et al. Resveratrol inhibits the formation of multiple-layered β-sheet oligomers of the human islet amyloid polypeptide segment 22–27. Biophys J. 2011;100(6):1550–1558.
   PubMed Web of Science ®Google Scholar
• Maedler K, Sergeev P, Ris F, et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. Clin Investig. 2002;110(6):851–860.
   Google Scholar
• Corbett JA, Sweetland MA, Wang JL, et al. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci U S A. 1993;90(5):1731–1735.
   PubMed Web of Science ®Google Scholar
• Chen F, Zhou X, Lin Y, et al. Resveratrol prevents interleukin-1β-induced dysfunction of pancreatic β-cells. J Biomed Res. 2010;24(5):381–388.
   PubMedGoogle Scholar
• Zeender E, Maedler K, Bosco D, et al. Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β. J Clin Endocrinol Metab. 2004;89(10):5059–5066.
   PubMed Web of Science ®Google Scholar
• Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res. 2011;2011:376509.
   PubMedGoogle Scholar
• Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med. 2013;23(3):266–280.
   PubMed Web of Science ®Google Scholar
• Farr S, Taher J, Adeli K. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Curr Drug Targets Cardiovasc Haematol Disord. 2014;14(2):126–136.
   Google Scholar
• Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol. 2012;23(1):56–61.
   PubMed Web of Science ®Google Scholar
• Xiao C, Dash S, Morgantini C, et al. Gut peptides are novel regulators of intestinal lipoprotein secretion: experimental and pharmacological manipulation of lipoprotein metabolism. Diabetes. 2015;64(7):2310–2318.
   PubMed Web of Science ®Google Scholar
• Dao TMA, Waget A, Klopp P, et al. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One. 2011;6(6):e20700.
   PubMed Web of Science ®Google Scholar
• Rouse M, Younès A, Egan JM. Resveratrol and curcumin enhance pancreatic β-cell function by inhibiting phosphodiesterase activity. J Endocrinol. 2014;223(2):107–117.
   PubMed Web of Science ®Google Scholar
• Fiori JL, Shin YK, Kim W, et al. Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes 2013;62(10):3500–3513.
   PubMed Web of Science ®Google Scholar
• Taylor BL, Liu FF, Sander M. Nkx6. 1 is essential for maintaining the functional state of pancreatic beta cells. Cell Rep. 2013;4(6):1262–1275.
   PubMed Web of Science ®Google Scholar
• Wang A, Liu M, Liu X, et al. Up-regulation of adiponectin by resveratrol the essential roles of the akt/foxo1 and amp-activated protein kinase signaling pathways and dsba-l. J Biol Chem. 2011;286:60–66.
   PubMed Web of Science ®Google Scholar
• Basciano H, Federico L, Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab. 2005;2:5.
   Google Scholar
• Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol. 2008;24(2):204–209.
   PubMed Web of Science ®Google Scholar
• Wei Y, Wang D, Topczewski F, et al. Fructose-mediated stress signaling in the liver: implications for hepatic insulin resistance. J Nutr Biochem. 2007;18(1):1–9.
   PubMed Web of Science ®Google Scholar
• Rutledge AC, Adeli K. Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr Rev. 2007;65:S13–S23.
   PubMed Web of Science ®Google Scholar
• Dekker MJ, Su Q, Baker C, et al. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab. 2010;299(5):E685–E694.
   PubMed Web of Science ®Google Scholar
• Lewis GF, Uffelman K, Naples M, et al. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology. 2005;146(1):247–255.
   PubMed Web of Science ®Google Scholar
• Mangaloglu L, Cheung RC, Van Iderstine SC, et al. Treatment with atorvastatin ameliorates hepatic very [ndash] low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: Evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism. 2002;51(4):409–418.
   PubMed Web of Science ®Google Scholar
• Taghibiglou C, Van-Iderstine S, Chen B, et al. Molecular mechanisms of hepatic insulin resistance in a fructose-fed/insulin resistant hamster model. Clin Biochem. 2000;33(3):240.
   Google Scholar
• Taghibiglou C, Carpentier A, Rudy D, et al. Mechanisms of hepatic VLDL overproduction in insulin resistance: evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem. 2000;275:8416–8425.
   PubMed Web of Science ®Google Scholar
• Adeli K, Taghibiglou C, Van Iderstine SC, et al. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11(5):170–176.
   PubMed Web of Science ®Google Scholar
• Qin B, Qiu W, Avramoglu RK, et al. Tumor necrosis factor-α induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes. 2007;56(2):450–461.
   PubMed Web of Science ®Google Scholar
• Shimamoto K, Ura N. Mechanisms of insulin resistance in hypertensive rats. Clin Exp Hypertens. 2006;28(6):543–552.
   PubMed Web of Science ®Google Scholar
• Babacanoglu C, Yildirim N, Sadi G, et al. Resveratrol prevents high-fructose corn syrup-induced vascular insulin resistance and dysfunction in rats. Food Chem Toxicol. 2013;60:160–167.
   PubMed Web of Science ®Google Scholar
• Cheng PW, Ho WY, Su YT, et al. Resveratrol decreases fructose‐induced oxidative stress, mediated by NADPH oxidase via an AMPK‐dependent mechanism. Br J Pharmacol. 2014;171(11):2739–2750.
   PubMed Web of Science ®Google Scholar
• İlhan N, Kaman D, İlhan N. The effects of resveratrol on biochemical changes in fructose-induced insulin resistance. J Clin Exp Invest. 2011;2:339–346.
   Google Scholar
• Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278(46):45777–45784.
   PubMed Web of Science ®Google Scholar
• Veličković N, Djordjevic A, Vasiljević A, et al. Tissue-specific regulation of inflammation by macrophage migration inhibitory factor and glucocorticoids in fructose-fed Wistar rats. Br J Nutr. 2013;110(03):456–465.
   PubMed Web of Science ®Google Scholar
• Pektas MB, Koca HB, Sadi G, et al. Dietary fructose activates insulin signaling and inflammation in adipose tissue: modulatory role of resveratrol. Biomed Res Int. 2016;2016:8014252.
   PubMed Web of Science ®Google Scholar
• Basciano H, Miller AE, Naples M, et al. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab. 2009;297(2):E462–E473.
   PubMed Web of Science ®Google Scholar
• Andrade JMO, Paraíso AF, de Oliveira MVM, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014;30(7):915–919.
   PubMed Web of Science ®Google Scholar
• Carantoni M, Abbasi F, Warmerdam F, et al. Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. Arterioscler Thromb Vasc Biol. 1998;18(5):762–767.
   PubMed Web of Science ®Google Scholar
• Linna MS, Ahotupa M, Kukkonen-Harjula K, et al. Co-existence of insulin resistance and high concentrations of circulating oxidized LDL lipids. Ann Med. 2015;47(5):394–398.
   PubMed Web of Science ®Google Scholar
• Couillard C, Ruel G, Archer WR, et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab. 2005;90(12):6454–6459.
   PubMed Web of Science ®Google Scholar
• Weinbrenner T, Schroder H, Escurriol V, et al. Circulating oxidized LDL is associated with increased waist circumference independent of body mass index in men and women. Am J Clin Nutr. 2006;83(1):30–35.
   PubMed Web of Science ®Google Scholar
• Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004;53(4):1068–1073.
   PubMed Web of Science ®Google Scholar
• Van Guilder GP, Hoetzer GL, Greiner JJ, et al. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity. 2006;14(12):2127–2131.
   PubMed Web of Science ®Google Scholar
• Njajou OT, Kanaya AM, Holvoet P, et al. Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study. Diabetes Metab Res Rev. 2009;25(8):733–739.
   PubMed Web of Science ®Google Scholar
• Kelly AS, Jacobs DR, Sinaiko AR, et al. Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatr Diab. 2010;11(8):552–555.
   PubMed Web of Science ®Google Scholar
• Niafar M, Nakhjavani M, Esteghamati A, et al. Relationship between lipid oxidation and insulin resistance in type 2 diabetes mellitus. Endocr Abst. 2009;20:P342.
   Google Scholar
• Park K, Gross M, Lee DH, et al. Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. Diab Care. 2009;32(7):1302–1307.
   PubMed Web of Science ®Google Scholar
• Li S, Kievit P, Robertson AK, et al. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab. 2013;2(3):256–269.
   PubMed Web of Science ®Google Scholar
• Kennedy DJ, Kuchibhotla S, Westfall KM, et al. A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signalling. Cardiovasc Res. 2011;89(3):604–613.
   PubMed Web of Science ®Google Scholar
• Kovanen PT, Pentikäinen MO. Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis. Curr Opin Lipidol. 2003;14(5):411–419.
   PubMed Web of Science ®Google Scholar
• Khalil A, Berrougui H. Mechanism of action of resveratrol in lipid metabolism and atherosclerosis. Clin Lipidol. 2009;4:527–531.
   Web of Science ®Google Scholar
• Upritchard JE, Sutherland W, Mann JI. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diab Care. 2000;23(6):733–738.
   PubMed Web of Science ®Google Scholar
• Belguendouz L, Fremont L, Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol. 1997;53(9):1347–1355.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9b):25–29.
   PubMed Web of Science ®Google Scholar
• Asato Y, Katsuren K, Ohshiro T, et al. Relationship between lipid abnormalities and insulin resistance in Japanese school children. Arterioscler Thromb Vasc Biol. 2006;26(12):2781–2786.
   PubMed Web of Science ®Google Scholar
• Anderson NJ, King MR, Delbruck L, et al. Role of insulin signaling impairment, adiponectin and dyslipidemia in peripheral and central neuropathy in mice. Dis Model Mech. 2014;7(6):625–633.
   PubMed Web of Science ®Google Scholar
• Penumathsa SV, Thirunavukkarasu M, Koneru S, et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol. 2007;42(3):508–516.
   PubMed Web of Science ®Google Scholar
• Rocha K, Souza G, Ebaid GX, et al. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol. 2009;47(6):1362–1367.
   PubMed Web of Science ®Google Scholar
• Adeli K, Theriault A. Insulin modulation of human apolipoprotein B mRNA translation: studies in an in vitro cell-free system from HepG2 cells. Biochem Cell Biol. 1992;70(12):1301–1312.
   PubMed Web of Science ®Google Scholar
• Karimian Pour N, Adeli K. Insulin silences apolipoprotein B mRNA translation by inducing intracellular traffic into cytoplasmic RNA granules. Biochemistry. 2011;50(32):6942–6950.
   PubMed Web of Science ®Google Scholar
• Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem. 2002;277(1):793–803.
   PubMed Web of Science ®Google Scholar
• Berthezene F. Hypertriglyceridemia: cause or consequence of insulin resistance? Horm Res. 1992;38(1–2):39–40.
   PubMedGoogle Scholar
• Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun. 2008;374(1):55–59.
   PubMed Web of Science ®Google Scholar
• Cho IJ, Ahn JY, Kim S, et al. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun. 2008;367(1):190–194.
   PubMed Web of Science ®Google Scholar
• Liu XM, Wu FH. Comparison of animal models of hyperlipidemia. Zhong Xi Yi Jie He Xue Bao. 2004;2(2):132–134.
   PubMedGoogle Scholar
• Dalboge LS, Pedersen PJ, Hansen G, et al. A hamster model of diet-induced obesity for preclinical evaluation of anti-obesity, anti-diabetic and lipid modulating agents. PLoS One. 2015;10(8):e0135634.
   PubMed Web of Science ®Google Scholar
• Pihlajamaki J, Gylling H, Miettinen TA, et al. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res. 2004;45(3):507–512.
   PubMed Web of Science ®Google Scholar
• Simonen PP, Gylling HK, Miettinen TA. Diabetes contributes to cholesterol metabolism regardless of obesity. Diab Care. 2002;25(9):1511–1515.
   PubMed Web of Science ®Google Scholar
• Paniagua JA, Lopez-Miranda J, Escribano A, et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes. 2002;51(8):2596–2603.
   PubMed Web of Science ®Google Scholar
• Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis. 2000;150(1):121–127.
   PubMed Web of Science ®Google Scholar
• Hao M, Head WS, Gunawardana SC, et al. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007;56(9):2328–2338.
   PubMed Web of Science ®Google Scholar
• Gnoni G, Paglialonga G. Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur J Clin Invest. 2009;39(3):211–218.
   PubMed Web of Science ®Google Scholar
• Jeon SM, Lee SA, Choi MS. Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice. J Med Food. 2014;17(3):310–316.
   PubMed Web of Science ®Google Scholar
• Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J. 2007;28(21):2637–2643.
   PubMed Web of Science ®Google Scholar
• Zern TL, Wood RJ, Greene C, et al. Grape polyphenols exert a cardioprotective effect in pre-and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr. 2005;135(8):1911–1917.
   PubMed Web of Science ®Google Scholar
• Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med. 2007;356(13):1364–1236.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–2122.
   PubMed Web of Science ®Google Scholar
• Karhapaa P, Malkki M, Laakso M. Isolated low HDL cholesterol. An insulin-resistant state. Diabetes. 1994;43(3):411–417.
   PubMed Web of Science ®Google Scholar
• Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221–1232.
   PubMed Web of Science ®Google Scholar
• Sevov M, Elfineh L, Cavelier LB. Resveratrol regulates the expression of LXR-alpha in human macrophages. Biochem Biophys Res Commun. 2006;348(3):1047–1054.
   PubMed Web of Science ®Google Scholar
• Tsang C, Higgins S, Duthie GG, et al. The influence of moderate red wine consumption on antioxidant status and indices of oxidative stress associated with CHD in healthy volunteers. Br J Nutr. 2005;93(02):233–240.
   PubMed Web of Science ®Google Scholar
• Rasouli N, Yao-Borengasser A, Varma V, et al. Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans. Arterioscler Thromb Vasc Biol. 2009;29(9):1328–1335.
   PubMed Web of Science ®Google Scholar
• Iannelli P, Zarrilli V, Varricchio E, et al. The dietary antioxidant resveratrol affects redox changes of PPARα activity. Nutr Metab Cardiovasc Dis. 2007;17(4):247–256.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luo Z, Ma L, et al. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor γ activation. Int J Mol Cell Med. 2010;25(5):729–734.
   PubMed Web of Science ®Google Scholar
• Kassaee SM, Goodarzi MT, Abbasi Oshaghi E. Antioxidant, antiglycation and anti-hyperlipidemic effects of Trigonella foenum and Cinnamon in type 2 diabetic rats. Jundishapur J Nat Pharm Prod. 2016;e38414 (in press). doi: 10.17795/jjnpp-38414.
   Google Scholar
• Goodarzi MT, Khodadadi I, Tavilani H, Abbasi Oshaghi E. The role of Anethum graveolens L. (dill) in the management of diabetes. J Trop Med. 2016;2016:1098916.
   PubMed Web of Science ®Google Scholar
• Moridi H, Karimi J, Sheikh N, et al. Resveratrol-dependent down-regulation of receptor for advanced glycation End-products and oxidative stress in kidney of rats with diabetes. Int J Endocrinol Metab. 2015; 13(2):e23542.
   PubMed Web of Science ®Google Scholar
• Khazaei M, Karimi J, Sheikh N, et al. Effects of resveratrol on receptor for advanced glycation end products (RAGE) expression and oxidative stress in the liver of rats with type 2 diabetes. Phytother Res. 2016;30(1):66–71.
   PubMed Web of Science ®Google Scholar
• Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome – an allostatic perspective. Biochim Biophys Acta. 2010;1801(3):338–349.
   PubMed Web of Science ®Google Scholar
• Shang J, Sun H, Xiao H. Resveratrol improves non‐alcoholic fatty liver disease by activating amp‐activated protein kinase1. Acta Pharmacol Sin. 2008;29(6):698–706.
   PubMed Web of Science ®Google Scholar
• Plomgaard P, Bouzakri K, Krogh-Madsen R, et al. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54(10):2939–2945.
   PubMed Web of Science ®Google Scholar
• Zarei S, Saidijam M, Karimi J, et al. Effect of resveratrol on resistin and apelin gene expressions in adipose tissue of diabetic rats. Turk J Med Sci. 2016;46(5):1561–1567.
   PubMed Web of Science ®Google Scholar
• Asadi S, Goodarzi MT, Saidijam M, et al. Resveratrol attenuates visfatin and vaspin genes expression in adipose tissue of rats with type 2 diabetes. Iran J Basic Med Sci. 2015;18(6):537–543.
   PubMed Web of Science ®Google Scholar
• Szkudelska K, Nogowski L, Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol. 2009;113(1):17–24.
   PubMed Web of Science ®Google Scholar
• Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12(20):3182–3194.
   PubMed Web of Science ®Google Scholar
• Chen S, Li Z, Li W, et al. Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK. Can J Physiol Pharmacol. 2011;89(11):793–799.
   PubMed Web of Science ®Google Scholar
• Rayalam S, Yang JY, Ambati S, et al. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res. 2008;22(10):1367–1371.
   PubMed Web of Science ®Google Scholar
• Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev. 1998;78(3):783–809.
   PubMed Web of Science ®Google Scholar
• Gerhart‐Hines Z, Rodgers JT, Bare O, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC‐1α. EMBO J. 2007;26(7):1913–1923.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Sun J, Xia S, Tang X, et al. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct. 2014;5(6):1241–1249.
   PubMed Web of Science ®Google Scholar
• Girousse A, Tavernier G, Valle C, et al. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol. 2013;11(2):e1001485.
   PubMed Web of Science ®Google Scholar
• Morigny P, Houssier M, Mouisel E, et al. Adipocyte lipolysis and insulin resistance. Biochimie. 2016;125:259–266.
   PubMed Web of Science ®Google Scholar
• Ertunc ME, Sikkeland J, Fenaroli F, et al. Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J Lipid Res. 2015;56(2):423–434.
   PubMed Web of Science ®Google Scholar
• Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol. 2005;25(10):2062–2068.
   PubMed Web of Science ®Google Scholar
• Harriman G, Greenwood J, Bhat S, et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci USA. 2016;113(13):E1796–E1805.
   PubMed Web of Science ®Google Scholar
• Schadinger SE, Bucher NL, Schreiber BM, et al. PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab. 2005;288(6):E1195–E1205.
   PubMed Web of Science ®Google Scholar
• Alberdi G, Rodriguez VM, Miranda J, et al. Changes in white adipose tissue metabolism induced by resveratrol in rats. Nutr Metab (Lond). 2011;8(1):29.
   PubMed Web of Science ®Google Scholar
• Park J, Rho HK, Kim KH, et al. Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol Cell Biol. 2005;25(12):5146–5157.
   PubMed Web of Science ®Google Scholar
• Ham M, Choe SS, Shin KC, et al. Glucose-6-phosphate dehydrogenase deficiency improves insulin resistance with reduced adipose tissue inflammation in obesity. Diabetes. 2016;65(9):2624–2638.
   PubMed Web of Science ®Google Scholar
• Basciano H, Miller A, Baker C, et al. LXRα activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins. Am J Physiol Gastrointest Liver Physiol. 2009;297(2):G323–G332.
   PubMed Web of Science ®Google Scholar
• Taghibiglou C, Rudy D, Van Iderstine SC, et al. Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes. J Lipid Res. 2000;41(4):499–513.
   PubMed Web of Science ®Google Scholar
• Casaschi A, Maiyoh GK, Adeli K, et al. Increased diacylglycerol acyltransferase activity is associated with triglyceride accumulation in tissues of diet-induced insulin-resistant hyperlipidemic hamsters. Metabolism. 2005;54(3):403–409.
   PubMed Web of Science ®Google Scholar
• Carpentier A, Taghibiglou C, Leung N, et al. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem. 2002;277(32):28795–28802.
   PubMed Web of Science ®Google Scholar
• Au CS, Wagner A, Chong T, et al. Insulin regulates hepatic apolipoprotein B production independent of the mass or activity of Akt1/PKBα. Metabolism. 2004;53(2):228–235.
   PubMed Web of Science ®Google Scholar
• Avramoglu RK, Adeli K. Hepatic regulation of apolipoprotein B. Rev Endocr Metab Disord. 2004;5(4):293–301.
   PubMed Web of Science ®Google Scholar
• Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci. 2003;8(3):464–476.
   Google Scholar
• Jin SH, Yang JH, Shin BY, et al. Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction. Toxicol Appl Pharmacol. 2013;271(1):95–105.
   PubMed Web of Science ®Google Scholar
• Garcia-Serrano S, Moreno-Santos I, Garrido-Sanchez L, et al. Stearoyl-CoA desaturase-1 is associated with insulin resistance in morbidly obese subjects. Mol Med. 2011;17(3–4):273–280.
   PubMed Web of Science ®Google Scholar
• Turcotte LP, Fisher JS. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys Ther. 2008;88(11):1279–1296.
   PubMed Web of Science ®Google Scholar
• Cooney GJ, Thompson AL, Furler SM, et al. Muscle long-chain acyl CoA esters and insulin resistance. Ann NY Acad Sci. 2002;967:196–207.
   PubMed Web of Science ®Google Scholar
• Itani SI, Ruderman NB, Schmieder F, et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002;51(7):2005–2011.
   PubMed Web of Science ®Google Scholar
• Dolinsky VW, Jones KE, Sidhu RS, et al. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J Physiol. 2012;590(11):2783–2799.
   PubMed Web of Science ®Google Scholar
• Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421–433.
   PubMed Web of Science ®Google Scholar
• Kim SK, Joe Y, Zheng M, et al. Resveratrol induces hepatic mitochondrial biogenesis through the sequential activation of nitric oxide and carbon monoxide production. Antioxid Redox Signal. 2014;20(16):2589–2605. doi:10.1002/mnfr.201600653
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Y, Su W, et al. Resveratrol attenuates mitochondrial dysfunction in the liver of intrauterine growth retarded suckling piglets by improving mitochondrial biogenesis and redox status. Mol Nutr Food Res. 2017;61(5).
   Web of Science ®Google Scholar
• Xu Z, Wang M, Mao H, et al. Effects of L-carnitine on growth performance, carcass composition, and metabolism of lipids in male broilers. Poult Sci. 2003;82(3):408–413.
   PubMed Web of Science ®Google Scholar
• Bruce CR, Hoy AJ, Turner N, et al. Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes. 2009;58(3):550–558.
   PubMed Web of Science ®Google Scholar
• Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011;94(1):58–65.
   PubMed Web of Science ®Google Scholar
• Purchiaroni F, Tortora A, Gabrielli M, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 2013;17(3):323–333.
   PubMed Web of Science ®Google Scholar
• Moreno-Indias I, Cardona F, Tinahones FJ, et al. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol. 2014;5:190.
   PubMed Web of Science ®Google Scholar
• Nagpal R, Yadav H, Marotta F. Gut microbiota: the next-gen frontier in preventive and therapeutic medicine? Front Med. 2014;1:15.
   Google Scholar
• Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diab Care. 2010;33(10):2277–2284.
   PubMed Web of Science ®Google Scholar
• Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31(6):817–844.
   PubMed Web of Science ®Google Scholar
• Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772.
   PubMed Web of Science ®Google Scholar
• Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology. 2016;31(4):283–293.
   PubMed Web of Science ®Google Scholar
• Amar J, Chabo C, Waget A, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med. 2011;3(9):559–572.
   PubMed Web of Science ®Google Scholar
• Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292(2):G518–G525.
   PubMed Web of Science ®Google Scholar
• Murphy EA, Velazquez KT, Herbert KM. Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk. Curr Opin Clin Nutr Metab Care. 2015;18(5):515–520.
   PubMed Web of Science ®Google Scholar
• Rodes L, Khan A, Paul A, et al. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013;23(4):518–526.
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
   PubMed Web of Science ®Google Scholar
• Le TK, Hosaka T, Le TT, et al. Oral administration of Bifidobacterium spp. improves insulin resistance, induces adiponectin, and prevents inflammatory adipokine expressions. Biomed Res. 2014;35(5):303–310.
   PubMed Web of Science ®Google Scholar
• Kim SH, Huh CS, Choi ID, et al. The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo. J Appl Microbiol. 2014;117(3):834–845.
   PubMed Web of Science ®Google Scholar
• Cano PG, Santacruz A, Trejo FM, et al. Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice. Obesity (Silver Spring Md). 2013;21(11):2310–2321.
   PubMed Web of Science ®Google Scholar
• Holowacz S, Guigné C, Chêne G, et al. A multispecies Lactobacillus-and Bifidobacterium-containing probiotic mixture attenuates body weight gain and insulin resistance after a short-term challenge with a high-fat diet in C57/BL6J mice. Pharma Nutr. 2015;3(3):101–107.
   Google Scholar
• Larrosa M, Yanez-Gascon MJ, Selma MV, et al. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem. 2009;57(6):2211–2220.
   PubMed Web of Science ®Google Scholar
• Chen ML, Yi L, Zhang Y, et al. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-Induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. MBio. 2016;7(2):e02210–e02215.
   Web of Science ®Google Scholar
• Bereswill S, Munoz M, Fischer A, et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One. 2010;5(12):e15099.
   PubMed Web of Science ®Google Scholar
• Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–1103.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Sun J, Xie Z, et al. Propensity to high-fat diet-induced obesity in mice is associated with the indigenous opportunistic bacteria on the interior of Peyer's patches. J Clin Biochem Nutr. 2014;55(2):120–128.
   PubMed Web of Science ®Google Scholar
• Duca FA, Sakar Y, Lepage P, et al. Replication of obesity and associated signaling pathways through transfer of microbiota from obese-prone rats. Diabetes. 2014;63(5):1624–1636.
   PubMed Web of Science ®Google Scholar
• Jung MJ, Lee J, Shin NR, et al. Chronic repression of mTOR complex 2 induces changes in the gut microbiota of diet-induced obese mice. Sci Rep. 2016;6:30887.
   PubMed Web of Science ®Google Scholar
• Nohr MK, Dudele A, Poulsen MM, et al. LPS-enhanced glucose-stimulated insulin secretion is normalized by resveratrol. PLoS One. 2016;11(1):e0146840.
   PubMed Web of Science ®Google Scholar
• Namasivayam N. Chemoprevention in experimental animals. Ann NY Acad Sci. 2011;1215:60–71.
   PubMed Web of Science ®Google Scholar
• Wang N, Han Q, Wang G, et al. Resveratrol protects oxidative stress-induced intestinal epithelial barrier dysfunction by upregulating heme oxygenase-1 expression. Dig Dis Sci. 2016;61(9):2522–2534.
   PubMed Web of Science ®Google Scholar
• Ling KH, Wan ML, El-Nezami H, et al. Protective capacity of resveratrol, a natural polyphenolic compound, against deoxynivalenol-induced intestinal barrier dysfunction and bacterial translocation. Chem Res Toxicol. 2016;29(5):823–833.
   PubMed Web of Science ®Google Scholar
• Gao X, Liu X, Xu J, et al. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng. 2014;118(4):476–481.
   PubMed Web of Science ®Google Scholar
• Cardona F, Andres-Lacueva C, Tulipani S, et al. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem. 2013;24(8):1415–1422.
   PubMed Web of Science ®Google Scholar
• Deng YX, Shi QZ, Chen B, et al. Comparative pharmacokinetics of baicalin in normal and the type 2 diabetic rats after oral administration of the Radix scutellariae extract. Fitoterapia. 2012;83(8):1435–1442.
   PubMed Web of Science ®Google Scholar
• Liu L, Deng Y, Yu S, et al. Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats. Die Pharmazie. 2008;63(5):384–388.
   PubMed Web of Science ®Google Scholar
• Villarreal-Pérez JZ, Villarreal-Martínez JZ, Lavalle-González FJ, et al. Plasma and urine metabolic profiles are reflective of altered beta-oxidation in non-diabetic obese subjects and patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2014;6(1):129.
   PubMed Web of Science ®Google Scholar
• Etxeberria U, Arias N, Boque N, et al. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. J Nutr Biochem. 2015;26(6):651–660.
   PubMed Web of Science ®Google Scholar